Citations

Clear

1053 citation(s) found for "Andre, F".

Abstract P1-19-09: Updated subgroup tumor response of abemaciclib plus aromatase inhibitor for hormone receptor positive (HR+), HER2 negative advanced breast cancer (MONARCH 3)
O’Shaughnessy, Joyce , Huober, Jens , Andre, Valerie AnneMarie, Martin, Holly , Hardebeck, Molly Catherine , Johnston, Stephen , Martín, Miguel , Toi, Masakazu , Leo, Angelo Di , Goetz, Matthew P.

Mayo Clinic

Cancer Research | March 26, 2020 | Volume: 80 | Issue: 4_Supplement | Pages: P1-19-09-P1-19-09

10.1158/1538-7445.sabcs19-p1-19-09 Get It

Abstract Background: Abemaciclib plus nonsteroidal aromatase inhibitors (AI) demonstrated efficacy with a tolerable safety profile as initial treatment for postmenopausal women with HR+, HER2− advanced breast cancer in the MONARCH 3 trial. In the intent-to-treat (ITT) population, the updated progression-free survival (PFS) with 12 months of additional follow-up was 28.2 versus 14.8 months (HR [95% CI]: 0.525 [0.415, 0.665]; p<.0001) in the abemaciclib plus AI versus placebo plus AI arms, respectively. Here we report data from the additional 12 months of follow-up on tumor response for the ITT population and exploratory subgroups previously identified as significantly prognostic (Di Leo et al. 2018). Methods: In MONARCH 3, a randomized, double-blind, phase III trial, 493 postmenopausal women with HR+, HER2− advanced breast cancer and no prior systemic therapy in the advanced setting, received an AI (anastrozole or letrozole) plus abemaciclib or placebo. From the October 31, 2018 cutoff, secondary endpoints including objective response rate ([ORR], complete response [CR] + partial response [PR]), time to response (TTR), and duration of response ([DoR], time from a confirmed CR or PR until disease progression or death) were assessed in the ITT population and exploratory subgroups previously reported as significantly prognostic. Waterfall plots will be used to illustrate the magnitude of change in tumor size for each subgroup (to be presented). Results: In patients with measurable disease, the ORR was 62.5% (95% CI: 56.7, 68.2) in the abemaciclib plus AI arm and 44.7% (95% CI: 36.2, 53.2) in the placebo plus AI arm (p≤.001). Additional follow-up confirmed that all prognostic subgroups received benefit from the addition of abemaciclib to AI, consistent with the ITT population, as evidenced by change in ORR, with the largest effects observed in subgroups of patients with liver metastases, progesterone receptor-negative tumors, high grade tumors, or treatment-free interval of <36 months (Table). Median TTR was similar between the two treatment arms (abemaciclib plus AI: 3.62 months; placebo plus AI: 3.65 months), and this was generally consistent across subgroups. Responses were more durable in the abemaciclib plus AI arm (median DoR: 32.71 months; 95% CI: 25.74, -) versus the placebo plus AI arm (median DoR: 17.49 months; 95% CI: 11.61, 22.19), including in poor prognostic subgroups. Conclusions: Extended follow-up in the MONARCH 3 trial further confirmed that the addition of abemaciclib to AI is associated with durable tumor responses, including those in patients with clinically poor prognostic characteristics. References: Di Leo A et al. NPJ Breast Cancer. 2018;4:41. Clinical trial information: NCT02246621 This study was funded by Eli Lilly and Company Table: Objective Response RateAbemaciclib + AIPlacebo + AIORR ChangeNn (%)Nn (%)%Measurable disease population269168 (62.5)13259 (44.7)17.8Liver metastasesYes4727 (57.45)306 (20.00)37.45No222141 (63.51)10253 (51.96)11.55Progesterone receptor statusNegative6137 (60.66)298 (27.59)33.07Positive206130 (63.11)10351 (49.51)13.60Treatment-free interval<36 months3117 (54.84)225 (22.73)32.11≥36 months7442 (56.76)3216 (50.00)6.76Tumor gradeHigh5739 (68.42)2811 (39.29)29.13Intermediate/ Low13992 (66.19)7535 (46.67)19.52ECOG PS111275 (66.96)5022 (44.00)22.96015793 (59.24)8237 (45.12)14.12Bone-only diseaseNo256162 (63.28)12253 (43.44)19.84YesNA*NA*NA*NA*NA*N= total number of patients in each subgroup; n= number of responder patients; NA=not applicable*Response rate not reported for bone-only disease because majority of lesions were not measurable Citation Format: Joyce O’Shaughnessy, Stephen Johnston, Miguel Martin, Jens Huober, Masakazu Toi, Valerie AnneMarie Andre, Holly Rene Martin, Molly Catherine Hardebeck, Angelo Di Leo, Matthew Philip Goetz. Updated subgroup tumor response of abemaciclib plus aromatase inhibitor for hormone receptor positive (HR+), HER2 negative advanced breast cancer (MONARCH 3) [abstract]. In: Proceedings of the 2019 San Antonio Breast Cancer Symposium; 2019 Dec 10-14; San Antonio, TX. Philadelphia (PA): AACR; Cancer Res 2020;80(4 Suppl):Abstract nr P1-19-09.
Functional informed genome‐wide interaction analysis of body mass index, diabetes and colorectal cancer risk
Xia, Zhiyu , Petersen, Paneen S., Qi, Lihong , Kim, Andre E. , Figueiredo, Jane C. , Nan, Hongmei , Berndt, Sonja I. , Casey, Graham , Conti, David V. , Gallinger, Steven , Gauderman, W. James, Gruber, Stephen B. , Gunter, Marc J. , Hoffmeister, Michael , Joshi, Amit D. , Li, Li , Lindor, Noralane M. , Moreno, Vı́ctor , Murphy, Neil , Nassir, Rami , Rennert, Gad , Wang, Xiaoliang , Woods, Michael O. , Brenner, Hermann , Slattery, Martha L. , Giovannucci, Edward L. , Chang‐Claude, Jenny, Peters, Ulrike , Kim, Andre E , Buchanan, Daniel D , Hoffmeister, Michael , Rennert, Gad , Moreno, Victor , Gunter, Marc J , Brenner, Hermann , Murphy, Neil , Nassir, Rami , Wang, Xiaoliang , Conti, David V , Nan, Hongmei , Su, Yu-Ru , Lin, Yi , Sakoda, Lori C. , Albanes, Demetrius , Bezieau, Stéphane , Bien, Stephanie A. , Buchanan, Daniel D. , Chan, Andrew T. , Drew, David A. , Giles, Graham G. , Jenkins, Mark A. , Marchand, Loı̈c Le , Lewinger, Juan Pablo , Newcomb, Polly A. , Ogino, Shuji , Song, Mingyang , Wolk, Alicja , White, Emily E. , Pharoah, Paul D.P. , Hsu, Li , Campbell, Peter T.

Mayo Clinic

Cancer Medicine | March 24, 2020 | Volume: 9 | Issue: 10 | Pages: 3563-3573

10.1002/cam4.2971 | PMID 32207560 Get It

AbstractBackgroundBody mass index (BMI) and diabetes are established risk factors for colorectal cancer (CRC), likely through perturbations in metabolic traits (e.g. insulin resistance and glucose homeostasis). Identification of interactions between variation in genes and these metabolic risk factors may identify novel biologic insights into CRC etiology.MethodsTo improve statistical power and interpretation for gene‐environment interaction (G × E) testing, we tested genetic variants that regulate expression of a gene together for interaction with BMI (kg/m2) and diabetes on CRC risk among 26 017 cases and 20 692 controls. Each variant was weighted based on PrediXcan analysis of gene expression data from colon tissue generated in the Genotype‐Tissue Expression Project for all genes with heritability ≥1%. We used a mixed‐effects model to jointly measure the G × E interaction in a gene by partitioning the interactions into the predicted gene expression levels (fixed effects), and residual G × E effects (random effects). G × BMI analyses were stratified by sex as BMI‐CRC associations differ by sex. We used false discovery rates to account for multiple comparisons and reported all results with FDR <0.2.ResultsAmong 4839 genes tested, genetically predicted expressions of FOXA1 (P = 3.15 × 10−5), PSMC5 (P = 4.51 × 10−4) and CD33 (P = 2.71 × 10−4) modified the association of BMI on CRC risk for men; KIAA0753 (P = 2.29 × 10−5) and SCN1B (P = 2.76 × 10−4) modified the association of BMI on CRC risk for women; and PTPN2 modified the association between diabetes and CRC risk in both sexes (P = 2.31 × 10−5).ConclusionsAggregating G × E interactions and incorporating functional information, we discovered novel genes that may interact with BMI and diabetes on CRC risk.
Abnormal myocardial expression of SAP97 is associated with arrhythmogenic risk
Musa, Hassan , Marcou, Cherisse A. , Herron, Todd J. , Makara, Michael, Tester, David J. , O’Connell, Ryan P. , Rosinski, Brad F., Guerrero‐Serna, Guadalupe , Milstein, Michelle L., Ye, Dan , Crotti, Lia , Nesterenko, Vladislav V., Castelletti, Silvia , Torchio, Margherita , Kotta, Maria‐Christina , Mohler, Peter J. , Ackerman, Michael J. , Anumonwo, Justus, Kotta, Maria-Christina , Schwartz, Peter J. , Crotti, Lia , Rocha, André Monteiro da , Dagradi, Federica , Antzelevitch, Charles

Mayo Clinic

American Journal of Physiology-Heart and Circulatory Physiology | March 20, 2020 | Volume: 318 | Issue: 6 | Pages: H1357-H1370

10.1152/ajpheart.00481.2019 | PMID 32196358 Get It

The gene encoding SAP97 ( DLG1) joins a growing list of genes encoding ion channel interacting proteins (ChIPs) identified as potential channelopathy-susceptibility genes because of their ability to regulate the trafficking, targeting, and modulation of ion channels that are critical for the generation and propagation of the cardiac electrical impulse. In this study we provide the first data supporting DLG1-encoded SAP97’s candidacy as a minor Brugada syndrome susceptibility gene.
The genetic architecture of the human cerebral cortex
Grasby, Katrina L. , Jahanshad, Neda , Painter, Jodie N. , Colodro‐Conde, Lucía , Bralten, Janita , Hibar, Derrek P. , Lind, Penelope A. , Pizzagalli, Fabrizio , Ching, Christopher R. K. , McMahon, Mary , Shatokhina, Natalia , Zsembik, Leo , Thomopoulos, Sophia I. , Zhu, Alyssa H. , Strike, Lachlan T. , Alhusaini, Saud , Almeida, Marcio , Amlien, Inge K. , Andersson, Micael , Ard, Tyler , Armstrong, Nicola J. , Bernard, Manon , Brouwer, Rachel M. , Buimer, Elizabeth E.L. , Bürger, Christian, Cannon, Dara M. , Chen, Qiang , Cheung, J. , Couvy‐Duchesne, Baptiste , Dale, Anders M. , Dalvie, Shareefa , Araujo, Tânia Kawasaki de , Zubicaray, Greig I. de , Zwarte, Sonja M. C. de , Braber, Anouk den , Doan, Nhat Trung , Dohm, Katharina , Ehrlich, Stefan , Engelbrecht, Hannah-Ruth , Erk, Susanne , Fan, Chun Chieh , Fedko, Iryna O. , Foley, Sonya , Fukunaga, Masaki , Ge, Tian , Giddaluru, Sudheer, Goldman, Aaron L. , Green, Melissa J. , Groenewold, Nynke A. , Grotegerd, Dominik , Gurholt, Tiril P. , Hansell, Narelle K. , Harris, Mathew A., Harrison, Marc , Haswell, Courtney C. , Hauser, Michael A. , Heslenfeld, Dirk J., Ho, New Fei , Hoehn, David , Holleran, Laurena , Hottenga, Jouke‐Jan , Jansen, Iris E. , Jockwitz, Christiane , Karama, Sherif , Kasperavičiūtė, Dalia , Kaufmann, Tobias , Kelly, Sinéad, Kikuchi, Masataka , Klein, Marieke , Knapp, Michael , Knodt, Annchen R. , Krämer, Bernd , Lancaster, T. , Lewis, Lindsay B. , Mathias, Samuel R. , Melzer, Tracy R. , Milaneschi, Yuri , Mirza‐Schreiber, Nazanin , Moreira, José C.V. , Mühleisen, Thomas W. , Müller‐Myhsok, Bertram , Najt, Pablo , Nakahara, Soichiro , Orfanos, Dimitri Papadopoulos , Pitcher, Toni L. , Quidé, Yann , Ragothaman, Anjanibhargavi , Reay, William R. , Redlich, Ronny , Repple, Jonathan , Riedel, Brandalyn C. , Risacher, Shannon L. , Rocha, Cristiane S. , Salminen, Lauren E. , Saremi, Arvin , Schlag, Fenja, Schmaal, Lianne , Secolin, Rodrigo , Shapland, Chin Yang , Shumskaya, Elena , Sønderby, Ida E. , Sprooten, Emma , Tansey, Katherine E. , Teumer, Alexander , Thalamuthu, Anbupalam , Tordesillas‐Gutiérrez, Diana , Turner, Jessica A. , Uhlmann, Anne , Meer, Dennis van der , Donkelaar, Marjolein M. J. van , Eijk, Liza van , Haren, Neeltje E.M. van , Tol, Marie‐José van , Walton, Esther , Wang, Mingyuan, Wardlaw, Joanna M. , Wen, Wei , Whelan, Christopher D. , Wittfeld, Katharina , Wolf, Christiane , Wolfers, Thomas , Wu, Jing , Yasuda, Clarissa Lin , Zaremba, Dario , Zhang, Zuo , Zwiers, Marcel P. , Artiges, Éric , Assareh, Amelia A., Ayesa‐Arriola, Rosa , Belger, Ayşenil , Brandt, Christine L., Brown, Gregory G. , Cichon, Sven , Curran, Joanne E. , Davies, Gareth E., Degenhardt, Franziska , Dennis, Michelle F. , Dietsche, Bruno, Doherty, Colin P. , Espiritu, Ryan, Gowland, Penny , Häusler, Alexander N. , Heindel, Walter , Ho, Beng‐Choon , Holsboer, Florian , Hosten, Norbert , Jang, MiHyun , Jansen, Andreas , Koops, Sanne, Krug, Axel , Lim, Kelvin O. , Luykx, Jurjen J. , Mather, Karen A. , Mattay, Venkata S. , Son, Jacqueline Mayoral-van , McEwen, Sarah , Melle, Ingrid , Morris, Derek W. , Nöthen, Markus M. , OʼLeary, Daniel S. , Martinot, Marie‐Laure Paillère , Preda, Adrian , Quinlan, Erin Burke , Rasser, Paul E. , Reppermund, Simone , Steen, Vidar M. , Tooney, Paul A. , Torres, Fábio R. , Veltman, Dick J. , Voyvodic, James , White, Tonya , Yamamori, Hidenaga , Adams, Hieab H.H. , Bis, Joshua C. , Debette, Stéphanie , DeCarli, Charles , Fornage, Myriam , Guðnason, Vilmundur , Hofer, Edith , Ikram, M. Arfan , Longstreth, W.T. , Roshchupkin, Gennady V. , Satizábal, Claudia L. , Schmidt, Reinhold, Initiative¶, Alzheimer’s Disease Neuroimaging, Initiative¶, Parkinson’s Progression Markers, Alvim, Marina K. M. , Ames, David, Anderson, Tim , Blangero, John , Brodaty, Henry , Brunner, Han G. , Buckner, Randy L. , Buitelaar, Jan K. , Cairns, Murray J. , Calhoun, Vince D. , Caseras, Xavier , Caspers, Svenja , Cavalleri, Gianpiero L. , Cendes, Fernando , Corvin, Aiden , Crespo‐Facorro, Benedicto , Dalrymple‐Alford, John C. , Geus, Eco J. C. de , Deary, Ian J. , Delanty, Norman, Depondt, Chantal, Desrivières, Sylvane , Donohoe, Gary , Fisher, Simon E. , Flor, Herta , Forstner, Andreas J. , Francks, Clyde , Franke, Barbara , Glahn, David C., Gruber, Oliver , Hariri, Ahmad R. , Hartman, Catharina A. , Hashimoto, Ryota , Heinz, Andreas , Hillegers, Manon H. J. , Hoekstra, Pieter J. , Hong, L. Elliot , Pol, Hilleke E. Hulshoff , Jönsson, Erik G. , Kahn, René S. , Kennedy, Martin A. , Kircher, Tilo , Hellard, Stéphanie Le , Loughland, Carmel M. , Martinot, Jean‐Luc , McMahon, Katie L. , Meyer‐Lindenberg, Andreas , Michie, Patricia T. , Morey, Rajendra A. , Mowry, Bryan , Nyberg, Lars , Oosterlaan, Jaap , Pantelis, Christos , Pausová, Zdenka , Penninx, Brenda W.J.H. , Polderman, Tinca J. C. , Posthuma, Daniëlle , Rowland, Laura M. , Sachdev, Perminder S. , Sämann, Philipp G. , Schall, Ulrich , Schumann, Günter , Scott, Rodney J. , Sim, Kang , Smoller, Jordan W., Sommer, Iris E. , Pourcain, Beaté St , Stein, Dan J. , Ent, Dennis van ‘t , Völzke, Henry , Weber, Bernd , Weinberger, Daniel R. , Wright, Margaret J. , Zhou, Juan , Thompson, Paul M. , Medland, Sarah E. , Seppi, Klaus , Duijn, Cornelia M. van , Jicha, Gregory A. , Vernooij, Meike W. , Mishra, Aniket , Saba, Yasaman , Shenkman, Elizabeth , Ghanbari, Mohsen , Knol, Maria J. , Witte, A. Veronica , Kremen, Sarah , DeCarli, Charles , McMahon, Mary Agnes B , Zsembik, Leo C P , Agartz, Ingrid , Almeida, Marcio A A , Amlien, Inge K , Andersson, Micael , Ard, Tyler , Armstrong, Nicola J , Atkins, Joshua R , Bernard, Manon , Brouwer, Rachel M , Buimer, Elizabeth E L , Chen, Qiang , Cheung, Joshua W , Couvy-Duchesne, Baptiste , Dale, Anders M , de Araujo, Tânia K , de Zubicaray, Greig I , Dohm, Katharina , Ehrlich, Stefan , Engelbrecht, Hannah-Ruth , Fedko, Iryna O , Ford, Judith M , Fukunaga, Masaki , Garrett, Melanie E , Green, Melissa J , Grotegerd, Dominik , Gurholt, Tiril P , Gutman, Boris A , Hansell, Narelle K , Harris, Mathew A , Harrison, Marc B , Haswell, Courtney C , Hauser, Michael , Herms, Stefan , Hoehn, David , Hoffmann, Per , Holleran, Laurena , Hoogman, Martine , Hottenga, Jouke-Jan , Ikeda, Masashi , Janowitz, Deborah , Jansen, Iris E , Jia, Tianye , Jockwitz, Christiane , Kanai, Ryota , Karama, Sherif , Kaufmann, Tobias , Kikuchi, Masataka , Klein, Marieke , Knodt, Annchen R , Krämer, Bernd , Lee, Phil H , Lewis, Lindsay B , Lopes-Cendes, Iscia , Luciano, Michelle , Macciardi, Fabio , Marquand, Andre F , Melzer, Tracy R , Mirza-Schreiber, Nazanin , Moreira, Jose C V , Mühleisen, Thomas W , Najt, Pablo , Olde Loohuis, Loes M , Orfanos, Dimitri Papadopoulos , Pearson, John F , Pitcher, Toni L , Quidé, Yann , Ragothaman, Anjanibhargavi , Reay, William R , Reinbold, Céline S , Repple, Jonathan , Richard, Geneviève , Riedel, Brandalyn C , Rocha, Cristiane S , Mota, Nina Roth , Salminen, Lauren , Saremi, Arvin , Saykin, Andrew J , Schlag, Fenja , Schofield, Peter R , Secolin, Rodrigo , Shapland, Chin Yang , Shen, Li , Shin, Jean , Shumskaya, Elena , Sprooten, Emma , Thalamuthu, Anbupalam , Turner, Jessica A , Vallerga, Costanza Ludovica , van Eijk, Liza , van Erp, Theo G M , van Haren, Neeltje E M , van Rooij, Daan , van Tol, Marie-José , Veldink, Jan H , Verhoef, Ellen , Walton, Esther , Wang, Mingyuan , Wang, Yunpeng , Wardlaw, Joanna Marguerite , Wen, Wei , Westlye, Lars T , Witt, Stephanie H , Wittfeld, Katharina , Wolf, Christiane , Wolfers, Thomas , Wu, Jing Qin , Yasuda, Clarissa L , Zhang, Zuo , Artiges, Eric , Ayesa-Arriola, Rosa , Belger, Aysenil , Cichon, Sven , Curran, Joanne E , Dennis, Michelle F , Djurovic, Srdjan , Doherty, Colin P , Garijo, Daniel , Gowland, Penny A , Green, Robert C. , Häusler, Alexander N , Ho, Beng-Choon , Hoffmann, Wolfgang U , Holsboer, Florian , Homuth, Georg , Hosten, Norbert , Jack, Clifford R , Jang, MiHyun , Jansen, Andreas , Krug, Axel , Lim, Kelvin O , Luykx, Jurjen J , Mathalon, Daniel H , Mattay, Venkata S , McEwen, Sarah C , Melle, Ingrid , Morris, Derek W , Mueller, Bryon A. , Nordvik, Jan E , Nöthen, Markus M , O'Leary, Daniel S , Preda, Adrian , Rasser, Paul E , Ratnakar, Varun , Steen, Vidar M , Torres, Fábio R , Veltman, Dick J , Voyvodic, James T , Whelan, Robert , Yamamori, Hidenaga , Adams, Hieab H H , López, Oscar L. , Mazoyer, Bernard , Mosley, Thomas H. , Satizabal, Claudia L , Seshadri, Sudha , Alvim, Marina K M , Anderson, Tim J , Andreassen, Ole A , Bastin, Mark E , Beckham, Jean C , Boomsma, Dorret I , Brodaty, Henry , Buitelaar, Jan K , Bustillo, Juan R , Cahn, Wiepke , Cairns, Murray J , Calhoun, Vince D. , Carr, Vaughan J , Cavalleri, Gianpiero L , Corvin, Aiden , Crespo-Facorro, Benedicto , Dalrymple-Alford, John C , Dannlowski, Udo , de Geus, Eco J C , Depondt, Chantal , Desrivières, Sylvane , Donohoe, Gary , Espeseth, Thomas , Fisher, Simon E , Flor, Herta , Francks, Clyde , Franke, Barbara , Gollub, Randy L , Håberg, Asta K , Hartman, Catharina A , Henskens, Frans A , Hillegers, Manon H J , Hoekstra, Pieter J , Holmes, Avram J , Hulshoff Pol, Hilleke E , Jönsson, Erik G , Kennedy, Martin A , Kircher, Tilo T J , Kwok, John B J , Le Hellard, Stephanie , Martin, Nicholas G , McMahon, Katie L , Meyer-Lindenberg, Andreas , Michie, Patricia T , Morey, Rajendra A , Mowry, Bryan , Oosterlaan, Jaap , Ophoff, Roel A , Pantelis, Christos , Pausova, Zdenka , Penninx, Brenda W J H , Polderman, Tinca J C , Posthuma, Danielle , Rietschel, Marcella , Roffman, Joshua L , Sachdev, Perminder S , Schall, Ulrich , Sim, Kang , Sommer, Iris E , St Pourcain, Beate , Stein, Dan J , Toga, Arthur W , Trollor, Julian N , Van der Wee, Nic J A , van 't Ent, Dennis , Walter, Henrik , Weber, Bernd , Weinberger, Daniel R , Wright, Margaret J , Zhou, Juan , Stein, Jason L , Thompson, Paul M , Medland, Sarah E , de Zwarte, Sonja M C , Ching, Christopher R K , Thomopoulos, Sophia I , Cendes, Fernando , Teumer, Alexander , van Duijn, Cornelia M , Debette, Stephanie , Seppi, Klaus , Hashimoto, Ryota , Jicha, Gregory A , Ge, Tian , Kremen, Sarah , Agartz, Ingrid , Alnæs, Dag , Ashley‐Koch, Allison E. , Bülow, Robin , Bürger, Christian, Chakravarty, M. Mallar , Dohm, Katharina , Lam, Max , Lett, Tristram A. P. , Lopes‐Cendes, Íscia , Nho, Kwangsik T. , Pütz, Benno , Rashid, Faisal M. , Saykin, Andrew J. , Schofield, Peter R. , Shen, Li , Veldink, Jan H. , Witt, Stephanie H. , Gil, Yolanda , Jack, Clifford R. , Kimbrel, Nathan A. , Kolskår, Knut K. , Matthews, Sarah , Nauck, Matthias A. , Opel, Nils , Pike, G. Bruce , Launer, Lenore J. , Mosley, Thomas H. , Seshadri, Sudha , Yang, Qiong , Initiative¶, Alzheimer’s Disease Neuroimaging, Initiative¶, Parkinson’s Progression Markers, Andreassen, Ole A. , Vásquez, Alejandro Arias , Bastin, Mark E. , Baune, Bernhard , Fernández, Guillén , Grabe, Hans Jörgen , Hopkins, William Donald , Jernigan, Terry L. , Kochunov, Peter V , Kwok, John B. , Martin, Nicholas G. , McDonald, Colm , Ophoff, Roel A. , Paus, Tomáš , Sisodiya, Sanjay , Smoller, Jordan W. , Toga, Arthur W. , Walter, Henrik , Stein, Jason L.

Mayo Clinic

Science | March 19, 2020 | Volume: 367 | Issue: 6484 | Pages: No page available

10.1126/science.aay6690 | PMID 32193296 Get It

INTRODUCTION The cerebral cortex underlies our complex cognitive capabilities. Variations in human cortical surface area and thickness are associated with neurological, psychological, and behavioral traits and can be measured in vivo by magnetic resonance imaging (MRI). Studies in model organisms have identified genes that influence cortical structure, but little is known about common genetic variants that affect human cortical structure. RATIONALE To identify genetic variants associated with human cortical structure at both global and regional levels, we conducted a genome-wide association meta-analysis of brain MRI data from 51,665 individuals across 60 cohorts. We analyzed the surface area and average thickness of the whole cortex and 34 cortical regions with known functional specializations. RESULTS We identified 369 nominally genome-wide significant loci ( P < 5 × 10 −8 ) associated with cortical structure in a discovery sample of 33,992 participants of European ancestry. Of the 360 loci for which replication data were available, 241 loci influencing surface area and 66 influencing thickness remained significant after replication, with 237 loci passing multiple testing correction ( P < 8.3 × 10 −10 ; 187 influencing surface area and 50 influencing thickness). Common genetic variants explained 34% (SE = 3%) of the variation in total surface area and 26% (SE = 2%) in average thickness; surface area and thickness showed a negative genetic correlation ( r G = −0.32, SE = 0.05, P = 6.5 × 10 −12 ), which suggests that genetic influences have opposing effects on surface area and thickness. Bioinformatic analyses showed that total surface area is influenced by genetic variants that alter gene regulatory activity in neural progenitor cells during fetal development. By contrast, average thickness is influenced by active regulatory elements in adult brain samples, which may reflect processes that occur after mid-fetal development, such as myelination, branching, or pruning. When considered together, these results support the radial unit hypothesis that different developmental mechanisms promote surface area expansion and increases in thickness. To identify specific genetic influences on individual cortical regions, we controlled for global measures (total surface area or average thickness) in the regional analyses. After multiple testing correction, we identified 175 loci that influence regional surface area and 46 that influence regional thickness. Loci that affect regional surface area cluster near genes involved in the Wnt signaling pathway, which is known to influence areal identity. We observed significant positive genetic correlations and evidence of bidirectional causation of total surface area with both general cognitive functioning and educational attainment. We found additional positive genetic correlations between total surface area and Parkinson’s disease but did not find evidence of causation. Negative genetic correlations were evident between total surface area and insomnia, attention deficit hyperactivity disorder, depressive symptoms, major depressive disorder, and neuroticism. CONCLUSION This large-scale collaborative work enhances our understanding of the genetic architecture of the human cerebral cortex and its regional patterning. The highly polygenic architecture of the cortex suggests that distinct genes are involved in the development of specific cortical areas. Moreover, we find evidence that brain structure is a key phenotype along the causal pathway that leads from genetic variation to differences in general cognitive function. Identifying genetic influences on human cortical structure. ( A ) Measurement of cortical surface area and thickness from MRI. ( B ) Genomic locations of common genetic variants that influence global and regional cortical structure. ( C ) Our results support the radial unit hypothesis that the expansion of cortical surface area is driven by proliferating neural progenitor cells. ( D ) Cortical surface area shows genetic correlation with psychiatric and cognitive traits. Error bars indicate SE. IMAGE CREDITS: (A) K. COURTNEY; (C) M. R. GLASS
Erdheim-Chester disease: consensus recommendations for evaluation, diagnosis, and treatment in the molecular era
Goyal, Gaurav , Heaney, Mark , Collin, Matthew , Cohen‐Aubart, Fleur , Durham, Benjamin H. , Hershkovitz‐Rokah, Oshrat , Girschikofsky, Michael , Jacobsen, Eric D. , Toyama, Kazuhiro, Goodman, Aaron M. , Hendrie, Paul C. , Estrada‐Veras, Juvianee , Shpilberg, Ofer , Abdo, André , Kurokawa, Mineo , Mazor, Roei David , Jankú, Filip , Haroche, Julien , Goyal, Guarav , Collin, Matthew , Hershkovitz-Rokah, Oshrat , Mazor, Roei D , Durham, Benjamin , Vaglio, Augusto , Cao, Xin-Xin , Dagna, Lorenzo , McClain, Kenneth L. , Picarsic, Jennifer , Go, Ronald S. , Diamond, Eli L.

Mayo Clinic

Blood | March 18, 2020 | Volume: 135 | Issue: 22 | Pages: 1929-1945

10.1182/blood.2019003507 | PMID 32187362 Get It

Abstract Erdheim-Chester disease (ECD) is a rare histiocytosis that was recently recognized as a neoplastic disorder owing to the discovery of recurrent activating MAPK (RAS-RAF-MEK-ERK) pathway mutations. Typical findings of ECD include central diabetes insipidus, restrictive pericarditis, perinephric fibrosis, and sclerotic bone lesions. The histopathologic diagnosis of ECD is often challenging due to nonspecific inflammatory and fibrotic findings on histopathologic review of tissue specimens. Additionally, the association of ECD with unusual tissue tropism and an insidious onset often results in diagnostic errors and delays. Most patients with ECD require treatment, except for a minority of patients with minimally symptomatic single-organ disease. The first ECD consensus guidelines were published in 2014 on behalf of the physicians and researchers within the Erdheim-Chester Disease Global Alliance. With the recent molecular discoveries and the approval of the first targeted therapy (vemurafenib) for BRAF-V600–mutant ECD, there is a need for updated clinical practice guidelines to optimize the diagnosis and treatment of this disease. This document presents consensus recommendations that resulted from the International Medical Symposia on ECD in 2017 and 2019. Herein, we include the guidelines for the clinical, laboratory, histologic, and radiographic evaluation of ECD patients along with treatment recommendations based on our clinical experience and review of literature in the molecular era.
Lenalidomide in relapsed/refractory mantle cell lymphoma post-bortezomib: Subgroup analysis of the MCL-001 study.
Williams, Michael E., Sinha, Rajni, Drach, Johannes, Ramchandren, Radhakrishnan , Zhang, Lei , Cicero, Sherri, Goy, Andre Henri , Beşışık, Sevgi Kalayoğlu , Fu, Tommy , Witzig, Thomas E.

Mayo Clinic

Journal of Clinical Oncology | March 12, 2020 | Volume: 31 | Issue: 15_suppl | Pages: 8534-8534

10.1200/jco.2013.31.15_suppl.8534 Get It

8534 Background: Lenalidomide, an immunomodulatory agent with antitumor and antiproliferative effects, demonstrated rapid and durable efficacy in patients with relapsed/refractory mantle cell lymphoma (MCL) post-bortezomib in the phase II multicenter MCL-001 study. The objective of this analysis was to explore the efficacy of lenalidomide across patient subgroups. Methods: Single-agent lenalidomide was administered at 25 mg/d PO on days 1-21 of a 28-day cycle until disease progression or intolerability; primary endpoints were overall response rate (ORR) and duration of response (DOR) determined by an independent central review committee per modified IWG criteria. Exploratory analyses of ORR and DOR for subgroups were predefined and prospectively conducted. Results: Patients with relapsed/refractory MCL (N=134) had a median age of 67 y, with a median of 4 prior therapies (range, 2-10). The ORR was 28% (7.5% CR/CRu) and DOR was 16.6 months (95% CI, 7.7-26.7). Lenalidomide treatment provided consistent ORR and DOR across all subgroups analyzed by demographics, baseline disease status and prior therapy (Table). High vs normal baseline LDH was the only significant factor by univariate and multivariate logistic regression analysis of ORR (odds ratio=0.193; p=0.002). Conclusions: Single-agent lenalidomide provided consistent clinical benefit in patients with relapsed/refractory MCL post-bortezomib irrespective of patient subgroups at baseline with the exception of LDH. Clinical trial information: NCT00737529. [Table: see text]
Combined analysis of single-agent lenalidomide in relapsed/refractory mantle cell lymphoma.
Sinha, Rajni, Williams, Michael E., Drach, Johannes, Ramchandren, Radhakrishnan , Zhang, Lei , Cicero, Sherri, Witzig, Thomas E. , Vose, Julie M. , Zinzani, Pier Luigi , Habermann, Thomas M. , Tuscano, Joseph M. , Beşışık, Sevgi Kalayoğlu , Fu, Tommy , Goy, Andre Henri

Mayo Clinic

Journal of Clinical Oncology | March 12, 2020 | Volume: 31 | Issue: 15_suppl | Pages: 8533-8533

10.1200/jco.2013.31.15_suppl.8533 Get It

8533 Background: Mantle cell lymphoma (MCL) is an aggressive form of non-Hodgkin lymphoma (NHL) with poor prognosis. The immunomodulatory agent lenalidomide shows consistent activity with tolerable safety in multiple phase II studies of relapsed/refractory aggressive NHL (NHL-002 and NHL-003) and MCL post-bortezomib (MCL-001). This pooled analysis further examined the efficacy and safety of single-agent lenalidomide in patients with relapsed/refractory MCL. Methods: Single-agent lenalidomide was given 25 mg/d PO on days 1-21 of 28-day cycles as tolerated for 52 weeks (NHL-002) or until disease progression (NHL-003 and MCL-001). All MCL patients received ≥1 prior treatment, including bortezomib in MCL-001. Efficacy data were examined by independent central review for MCL-001 and NHL-003 and by investigators for NHL-002. Results: 206 patients with relapsed/refractory MCL were studied. The median age was 67 y (range 33-84; 63% ≥65 y), 91% stage III/IV disease and 51% had received ≥4 prior regimens (76% prior bortezomib). Overall response rate (ORR) with lenalidomide was 32% (10% CR/CRu), with a median time to response of 2.1 months and median duration of response (DOR) of 16.6 months (not yet reached in patients with CR/CRu; Table). Kaplan-Meier estimates for median PFS and OS were 5.4 and 23.9 months, respectively. Mean daily dose of lenalidomide was 21 mg. Grade 3/4 AEs included neutropenia (44%), thrombocytopenia (29%), anemia (11%), and fatigue (7%). Other any-grade AEs included tumor flare reaction (7%), venous thromboembolic events (7%), and invasive second primary malignancies (3%). Conclusions: Lenalidomide produced rapid and durable responses in patients with relapsed/refractory MCL, and exhibited a predictable safety profile among 3 phase II studies of lenalidomide in heavily pretreated patients, including prior treatment with bortezomib. Clinical trial information: MCL-001: NCT00737529; NHL-002: NCT00179660; NHL-003: NCT00413036. [Table: see text]
Phase I expansion trial of an oral TORC1/TORC2 inhibitor (CC-223) in diffuse large B-cell lymphoma (DLBCL) and multiple myeloma (MM).
Varga, Andréa , Paz‐Ares, Luis , Mita, Monica , Delord, Jean‐Pierre , Gutierrez, Martin , James, Angela , Xu, Shuichan , Wu, Xiaoling , Carmichael, James, Chopra, Rajesh, Hege, Kristen , Goy, Andre Henri , Ribrag, Vincent , Witzig, Thomas E. , Ocio, Enrique M. , Meyer, Tim , Münster, Pamela N. , Mahipal, Amit , Arkenau, Hendrik‐Tobias , Wong, Lilly M.

Mayo Clinic

Journal of Clinical Oncology | March 12, 2020 | Volume: 31 | Issue: 15_suppl | Pages: 8522-8522

10.1200/jco.2013.31.15_suppl.8522 Get It

8522 Background: CC-223 is an ATP-competitive inhibitor of the mTOR kinase, including both TORC1 and TORC2 complexes. CC-223 was selected to address resistance of rapamycin analogues mediated by TORC2 activation. Methods: Following establishment of the MTD (reported at ASCO 2012), subjects with advanced DLBCL, MM and select solid tumors were enrolled in parallel expansion cohorts of up to 20 evaluable subjects. CC-223 was dosed at 45 mg once daily in 28 day cycles until disease progression. Results: As of 09 January, 2013, 35 subjects were enrolled including DLBCL (21) and MM (14). Results in solid tumor cohorts are reported separately. The most common (> 20%) related adverse events (all grades) were fatigue, hyperglycemia, rash, anorexia, nausea, vomiting and diarrhea. In addition, related serious adverse events included infection (2), pneumonitis (1), renal insufficiency (2), pancreatitis (1) and thrombocytopenia (1). CC-223 dose reduction was required in 9 subjects (27%), usually during cycle 1 or 2, and 4 additional subjects with DLBCL dropped out during cycle 1 due to toxicity. Systemic exposure was similar between the two tumor cohorts and was associated with inhibition of TORC1 (p4EBP1) and TORC2 (pAKT) biomarkers in blood cells. Reduction in glucose uptake (32 – 98% decrease) on PET imaging at day 15 was observed in 7/7 DLBCL subjects with results currently available. Three of 17 evaluable subjects with DLBCL had partial responses (PR) after 2 cycles; two with rapid and near complete regression (> 90%) of target lesions by CT and PET with PR confirmed and treatment ongoing at 6 and 8 cycles. Both had failed multiple prior treatment regimens (5 and 3, respectively), including autologous stem cell transplant (ASCT). No responses were observed in 10/14 evaluable subjects with MM although 2 subjects have prolonged stable disease (SD) with treatment ongoing at 12 and 14 cycles. Conclusions: Encouraging signals of biomarker and clinical activity were observed in DLBCL, including two near complete responses, which are ongoing. Due to dose reductions and interruptions, a starting dose of 30 mg QD is recommended for future studies. Clinical trial information: NCT01177397.
Accent-based nomograms (NGs) to predict time to recurrence (TTR) and overall survival (OS) in stage III colon cancer (CC).
Renfro, Lindsay A. , Loprinzi, Charles L. , Group, Adjuvant Colon Cancer Endpoints (ACCENT), Grothey, Axel , Saltz, Leonard B. , André, Thierry , Labianca, Roberto , Alberts, Steven R. , Yothers, Greg , Sargent, Daniel J. , Group, Adjuvant Colon Cancer Endpoints (ACCENT)

Mayo Clinic

Journal of Clinical Oncology | March 11, 2020 | Volume: 31 | Issue: 15_suppl | Pages: 3618-3618

10.1200/jco.2013.31.15_suppl.3618 Get It

3618 Background: Current prognostic tools and staging systems in CC use relatively few patient (pt) characteristics; including additional covariates may improve prediction. Using the large ACCENT database, we constructed clinically based NGs for OS and TTR in stage III CC that better separate pts into risk groups compared to AJCC v7 staging. Methods: 15,936 stage III pts accrued to phase III clinical trials since 1989 were used to construct Cox models for TTR and OS. Variables included age, sex, race, BMI, performance status, tumor grade, tumor stage, ratio of positive lymph nodes to nodes examined, number/location of primary tumors (any multiple versus single left, right, or transverse), and treatment (5FU variations vs. 5FU with oxaliplatin or irinotecan). Missing data (<18%) were imputed, continuous variables modeled with splines, and clinically relevant pairwise interactions included if p < 0.001. Final models were internally validated via bootstrapping for corrected calibration and C-indices for survival data. NG-defined risk tertiles were compared to AJCC v7 stage III for observed 3-year (yr) TTR and 5-yr OS for a subset of 7400 pts with complete data. Results: All variables were statistically and clinically significant for OS; age and race did not predict TTR. No meaningful interactions existed. NGs for OS and TTR were well calibrated and associated with C-indices of 0.66 and 0.65, respectively, vs. 0.58 and 0.59 for AJCC. NG risk tertiles were better separated than AJCC groups, (3-yr TTR, 5-yr OS below), with fewer mid-risk NG pts. Removing treatment from NGs did not affect performance (C=0.66 for OS and 0.65 for TTR). Conclusions: The proposed ACCENT NGs are internally valid and have the potential to aid prognostication, decision-making, and patient/physician communication in pts with stage III CC. [Table: see text]
NSABP B-38: Definitive analysis of a randomized adjuvant trial comparing dose-dense (DD) AC followed by paclitaxel (P) plus gemcitabine (G) with DD AC followed by P and with docetaxel, doxorubicin, and cyclophosphamide (TAC) in women with operable, node-po
Tang, Gong , Rastogi, Priya , Atkins, James N., Donnellan, Paul , Azar, Catherine A., Robidoux, André, Polikoff, Jonathan, Biggs, David D., Zapas, John L., Provencher, Louise , Perez, Edith A. , Costantino, Joseph P., Mamounas, Eleftherios P. , Swain, Sandra M. , Geyer, Charles E. , Fehrenbacher, Louis , Brufsky, Adam , Levine, Edward A. , Paik, Soonmyung , Mamounas, Eleftherios P. , Wolmark, Norman

Mayo Clinic

Journal of Clinical Oncology | March 11, 2020 | Volume: 30 | Issue: 15_suppl | Pages: LBA1000-LBA1000

10.1200/jco.2012.30.15_suppl.lba1000 Get It

LBA1000 The full, final text of this abstract will be available at abstract.asco.org at 12:01 AM (EDT) on Monday, June 4, 2012, and in the Annual Meeting Proceedings online supplement to the June 20, 2012, issue of Journal of Clinical Oncology. Onsite at the Meeting, this abstract will be printed in the Monday edition of ASCO Daily News.